Table 1.
Baseline characteristics
| Baseline characteristics |
nab-Paclitaxel plus carboplatin (n = 61) |
Gemcitabine plus carboplatin (n = 132) |
P-value |
|---|---|---|---|
| Age, mean, years | 68.7 | 67.9 | 0.57 |
| ≥ 60 years, n (%) | 51 (84) | 105 (80) | |
| ≥ 70 years, n (%) | 33 (54) | 59 (45) | |
| Sex, n (%) | |||
| Male | 40 (66) | 80 (61) | 0.51 |
| Female | 21 (34) | 52 (39) | 0.51 |
| Stage at index date, n (%) | |||
| IIIB | 3 (5) | 6 (5) | 0.91 |
| IV | 58 (95) | 126 (95) | |
| Treatments prior to first line, n (%) | |||
| Radiation | 19 (31) | 35 (27) | 0.61 |
| Surgery | 2 (3) | 2 (2) | |
| Adjuvant chemotherapy, n (%) | |||
| Did not receive | 58 (95) | 128 (97) | 0.54 |
| Received | 3 (5) | 4 (3) | |
| ECOG PS at first line, n (%)a | |||
| 0–1 | 17 (28) | 51 (39) | 0.15 |
| ≥2 | 4 (7) | 16 (12) | 0.24 |
| Unknown | 40 (66) | 65 (49) | 0.04 |
| Location of metastasis, n (%)a | |||
| Bone | 15 (25) | 28 (21) | 0.60 |
| Brain | 4 (7) | 6 (5) | 0.56 |
| Liver | 2 (3) | 14 (11) | 0.09 |
| CCI, meanb | 2.7 | 4.1 | 0.10 |
| Serum creatinine at first line, mean, mg/dL | 0.8 | 1.0 | 0.05 |
Notes:
a
Descriptive only due to missing values;
b
CCI comorbidities included cardiovascular disease, cancers, human immunodeficiency virus/AIDS, diabetes, renal disease, and others.
Abbreviations: CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status.